Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000666129 | SCV000790373 | likely pathogenic | Peroxisome biogenesis disorder 4A (Zellweger); Peroxisome biogenesis disorder 4B | 2017-03-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001043607 | SCV001207362 | likely pathogenic | Peroxisome biogenesis disorder | 2023-05-22 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 551145). This variant has not been reported in the literature in individuals affected with PEX6-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.0009%). This sequence change affects a donor splice site in intron 12 of the PEX6 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PEX6 are known to be pathogenic (PMID: 8670792, 19877282, 21031596). |
Baylor Genetics | RCV003472076 | SCV004201577 | likely pathogenic | Heimler syndrome 2 | 2024-01-24 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001276614 | SCV001463066 | likely pathogenic | Zellweger spectrum disorders | 2020-09-16 | no assertion criteria provided | clinical testing |